Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles. While many countries have seen a decline in investment in recent years ...

Merck will invest $275 million (250 million euros) in a new facility in Corsier-sur-Vevey, Switzerland. The Merck Biotech Development Center will be dedicated to biotech development and ...

More Swiss biotech gathers in Washington This content was published on Jun 23, 2003 More than 3,300 delegates from 50 countries, including scientists, investors and ministers have descended on ...

One of the drivers for this is a 25 percent higher rate of availability in European markets for innovative drugs from Swiss-based biotech companies. This is based on research conducted by IQVIA ...

In 2023, the Swiss Biotech Association reported that the life sciences sector—pharmaceuticals, vitamins and diagnostics—became the country’s largest export industry. Swiss biotech revenues ...

Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth #2345, showcasing the ...

Amgen unveils its KRas inhibitor in human clinical trials FDA’s shift from animal testing opens doors for organoid makers The biotech industry in Switzerland had a strong 2022, according to the ...

PARIS — L’Oréal has taken a minority stake in Swiss longevity biotech company Timeline. Terms of the deal, which was made through the beauty giant’s strategic venture capital fund Business ...

The company today announced the opening of its second space in biotech hub Basel, Switzerland. The 4,770 square metre space will offer ready-to-use laboratory spaces, along with essential ...

BERLIN, April 23 (Reuters) - Swiss biotech investor Xlife Sciences AG (XLS.S), opens new tab said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 ...

Ironwood Pharmaceuticals Inc. IRWD said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT for $17 a share in cash, or a total of about $1 billion, net of VectivBio’s cash ...